Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Expenses (2016 - 2025)

Cumberland Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $15.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 22.58% year-over-year to $15.0 million; the TTM value through Dec 2025 reached $47.3 million, up 26.16%, while the annual FY2025 figure was $47.3 million, 6.8% up from the prior year.
  • Operating Expenses for Q4 2025 was $15.0 million at Cumberland Pharmaceuticals, up from $10.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $15.0 million in Q4 2025 and bottomed at $4.0 million in Q3 2024.
  • The 5-year median for Operating Expenses is $10.9 million (2024), against an average of $11.0 million.
  • The largest annual shift saw Operating Expenses crashed 66.69% in 2024 before it surged 157.63% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $12.7 million in 2021, then fell by 10.04% to $11.4 million in 2022, then increased by 4.83% to $12.0 million in 2023, then rose by 2.72% to $12.3 million in 2024, then increased by 22.58% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Operating Expenses are $15.0 million (Q4 2025), $10.3 million (Q3 2025), and $11.6 million (Q2 2025).